Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results

Ida Franiak-Pietryga, Henryk Maciejewski, Dariusz Wolowiec, Aleksandra Salagacka, Jerzy Z. Blonski, Agnieszka Janus, Aleksandra Kotkowska, Ewa Wawrzyniak, Paolo Ghia, Marek Mirowski, Tadeusz Robak, Anna Korycka-Wolowiec

Research output: Contribution to journalArticle

Abstract

The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan ® Low Density Array for 96 gene transcripts was used. Those modifications followed two distinctive patterns largely overlapping the IGHV mutational status. In the IGHV-mutated group, the expression of many proapoptotic genes increased after treatment as compared to initial value. Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status.

Original languageEnglish
Pages (from-to)1134-1140
Number of pages7
JournalLeukemia Research
Volume36
Issue number9
DOIs
Publication statusPublished - Sep 2012

    Fingerprint

Keywords

  • Apoptosis
  • Chronic lymphocytic leukemia
  • Gene expression profiling
  • IGHV mutation
  • Microarray

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Franiak-Pietryga, I., Maciejewski, H., Wolowiec, D., Salagacka, A., Blonski, J. Z., Janus, A., Kotkowska, A., Wawrzyniak, E., Ghia, P., Mirowski, M., Robak, T., & Korycka-Wolowiec, A. (2012). Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results. Leukemia Research, 36(9), 1134-1140. https://doi.org/10.1016/j.leukres.2012.04.026